"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","platform_id","contact_name","contact_email","contact_laboratory","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","disease state:ch1","new distant metastasis:ch1","tissue:ch1"
"GSM3004865","Breast Cancer BC1789","GSM3004865","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004865/suppl/GSM3004865_SH67M21_Cell2.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3004866","Breast Cancer BC1821","GSM3004866","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004866/suppl/GSM3004866_SH67M32_Cell2.txt.gz","2565","64","metastatic breast cancer","No","Serum"
"GSM3004867","Breast Cancer BC1823","GSM3004867","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004867/suppl/GSM3004867_SH67M32_Cell4.txt.gz","2565","65","metastatic breast cancer","Yes","Serum"
"GSM3004868","Breast Cancer BC1824","GSM3004868","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004868/suppl/GSM3004868_SH67M33_Cell1.txt.gz","2565","64","metastatic breast cancer","No","Serum"
"GSM3004869","Breast Cancer BC1825","GSM3004869","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 37","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004869/suppl/GSM3004869_SH67M33_Cell2.txt.gz","2565","37","metastatic breast cancer","Yes","Serum"
"GSM3004870","Breast Cancer BC1826","GSM3004870","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 48","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004870/suppl/GSM3004870_SH67M33_Cell3.txt.gz","2565","48","metastatic breast cancer","No","Serum"
"GSM3004871","Breast Cancer BC1827","GSM3004871","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004871/suppl/GSM3004871_SH67M33_Cell4.txt.gz","2565","65","metastatic breast cancer","Yes","Serum"
"GSM3004872","Breast Cancer BC1828","GSM3004872","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 62","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004872/suppl/GSM3004872_SH67M34_Cell1.txt.gz","2565","62","metastatic breast cancer","No","Serum"
"GSM3004873","Breast Cancer BC1829","GSM3004873","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 69","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004873/suppl/GSM3004873_SH67M34_Cell2.txt.gz","2565","69","metastatic breast cancer","No","Serum"
"GSM3004874","Breast Cancer BC1830","GSM3004874","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 57","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004874/suppl/GSM3004874_SH67M34_Cell3.txt.gz","2565","57","metastatic breast cancer","No","Serum"
"GSM3004875","Breast Cancer BC1831","GSM3004875","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 62","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004875/suppl/GSM3004875_SH67M34_Cell4.txt.gz","2565","62","metastatic breast cancer","No","Serum"
"GSM3004876","Breast Cancer BC1832","GSM3004876","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 50","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004876/suppl/GSM3004876_SH67M35_Cell1.txt.gz","2565","50","metastatic breast cancer","No","Serum"
"GSM3004877","Breast Cancer BC1833","GSM3004877","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004877/suppl/GSM3004877_SH67M35_Cell2.txt.gz","2565","44","metastatic breast cancer","No","Serum"
"GSM3004878","Breast Cancer BC1834","GSM3004878","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004878/suppl/GSM3004878_SH67M35_Cell3.txt.gz","2565","44","metastatic breast cancer","No","Serum"
"GSM3004879","Breast Cancer BC1835","GSM3004879","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 53","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004879/suppl/GSM3004879_SH67M35_Cell4.txt.gz","2565","53","metastatic breast cancer","Yes","Serum"
"GSM3004880","Breast Cancer BC1836","GSM3004880","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004880/suppl/GSM3004880_SH67M36_Cell1.txt.gz","2565","59","metastatic breast cancer","Yes","Serum"
"GSM3004881","Breast Cancer BC1837","GSM3004881","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004881/suppl/GSM3004881_SH67M36_Cell2.txt.gz","2565","54","metastatic breast cancer","No","Serum"
"GSM3004882","Breast Cancer BC1838","GSM3004882","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004882/suppl/GSM3004882_SH67M36_Cell3.txt.gz","2565","60","metastatic breast cancer","No","Serum"
"GSM3004883","Breast Cancer BC1839","GSM3004883","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 43","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004883/suppl/GSM3004883_SH67M36_Cell4.txt.gz","2565","43","metastatic breast cancer","Yes","Serum"
"GSM3004884","Breast Cancer BC1840","GSM3004884","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 40","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004884/suppl/GSM3004884_SH67M37_Cell1.txt.gz","2565","40","metastatic breast cancer","No","Serum"
"GSM3004885","Breast Cancer BC1841","GSM3004885","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004885/suppl/GSM3004885_SH67M37_Cell2.txt.gz","2565","65","metastatic breast cancer","Yes","Serum"
"GSM3004886","Breast Cancer BC1842","GSM3004886","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 51","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004886/suppl/GSM3004886_SH67M37_Cell3.txt.gz","2565","51","metastatic breast cancer","No","Serum"
"GSM3004887","Breast Cancer BC1843","GSM3004887","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004887/suppl/GSM3004887_SH67M37_Cell4.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3004888","Breast Cancer BC1844","GSM3004888","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004888/suppl/GSM3004888_SH67M38_Cell1.txt.gz","2565","60","metastatic breast cancer","No","Serum"
"GSM3004889","Breast Cancer BC1845","GSM3004889","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004889/suppl/GSM3004889_SH67M38_Cell2.txt.gz","2565","59","metastatic breast cancer","Yes","Serum"
"GSM3004890","Breast Cancer BC1846","GSM3004890","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 66","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004890/suppl/GSM3004890_SH67M38_Cell3.txt.gz","2565","66","metastatic breast cancer","No","Serum"
"GSM3004891","Breast Cancer BC1847","GSM3004891","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 66","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004891/suppl/GSM3004891_SH67M38_Cell4.txt.gz","2565","66","metastatic breast cancer","No","Serum"
"GSM3004892","Breast Cancer BC1848","GSM3004892","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 52","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004892/suppl/GSM3004892_SH67M40_Cell1.txt.gz","2565","52","metastatic breast cancer","Yes","Serum"
"GSM3004893","Breast Cancer BC1849","GSM3004893","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 62","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004893/suppl/GSM3004893_SH67M40_Cell2.txt.gz","2565","62","metastatic breast cancer","Yes","Serum"
"GSM3004894","Breast Cancer BC1850","GSM3004894","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 38","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004894/suppl/GSM3004894_SH67M40_Cell3.txt.gz","2565","38","metastatic breast cancer","Yes","Serum"
"GSM3004895","Breast Cancer BC1851","GSM3004895","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 45","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004895/suppl/GSM3004895_SH67M40_Cell4.txt.gz","2565","45","metastatic breast cancer","No","Serum"
"GSM3004896","Breast Cancer BC1852","GSM3004896","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 74","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004896/suppl/GSM3004896_SH67M41_Cell1.txt.gz","2565","74","metastatic breast cancer","No","Serum"
"GSM3004897","Breast Cancer BC1853","GSM3004897","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 37","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004897/suppl/GSM3004897_SH67M41_Cell2.txt.gz","2565","37","metastatic breast cancer","No","Serum"
"GSM3004898","Breast Cancer BC1854","GSM3004898","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 47","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004898/suppl/GSM3004898_SH67M41_Cell3.txt.gz","2565","47","metastatic breast cancer","No","Serum"
"GSM3004899","Breast Cancer BC1855","GSM3004899","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004899/suppl/GSM3004899_SH67M41_Cell4.txt.gz","2565","44","metastatic breast cancer","Yes","Serum"
"GSM3004900","Breast Cancer BC1856","GSM3004900","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 63","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004900/suppl/GSM3004900_SH67M42_Cell1.txt.gz","2565","63","metastatic breast cancer","No","Serum"
"GSM3004901","Breast Cancer BC1857","GSM3004901","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004901/suppl/GSM3004901_SH67M42_Cell2.txt.gz","2565","54","metastatic breast cancer","No","Serum"
"GSM3004902","Breast Cancer BC1858","GSM3004902","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004902/suppl/GSM3004902_SH67M42_Cell3.txt.gz","2565","54","metastatic breast cancer","Yes","Serum"
"GSM3004903","Breast Cancer BC1859","GSM3004903","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004903/suppl/GSM3004903_SH67M42_Cell4.txt.gz","2565","59","metastatic breast cancer","Yes","Serum"
"GSM3004904","Breast Cancer BC1860","GSM3004904","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 63","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004904/suppl/GSM3004904_SH67M43_Cell1.txt.gz","2565","63","metastatic breast cancer","No","Serum"
"GSM3004905","Breast Cancer BC1861","GSM3004905","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 68","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004905/suppl/GSM3004905_SH67M44_Cell1.txt.gz","2565","68","metastatic breast cancer","No","Serum"
"GSM3004906","Breast Cancer BC1862","GSM3004906","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 46","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004906/suppl/GSM3004906_SH67T61_Cell3.txt.gz","2565","46","metastatic breast cancer","Yes","Serum"
"GSM3004907","Breast Cancer BC1863","GSM3004907","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 32","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004907/suppl/GSM3004907_SH67M44_Cell3.txt.gz","2565","32","metastatic breast cancer","Yes","Serum"
"GSM3004908","Breast Cancer BC1864","GSM3004908","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 47","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004908/suppl/GSM3004908_SH67T61_Cell4.txt.gz","2565","47","metastatic breast cancer","No","Serum"
"GSM3004909","Breast Cancer BC1866","GSM3004909","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 75","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004909/suppl/GSM3004909_SH67M45_Cell2.txt.gz","2565","75","metastatic breast cancer","No","Serum"
"GSM3004910","Breast Cancer BC1867","GSM3004910","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 47","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004910/suppl/GSM3004910_SH67M45_Cell3.txt.gz","2565","47","metastatic breast cancer","Yes","Serum"
"GSM3004911","Breast Cancer BC1868","GSM3004911","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004911/suppl/GSM3004911_SH67T62_Cell1.txt.gz","2565","65","metastatic breast cancer","No","Serum"
"GSM3004912","Breast Cancer BC1869","GSM3004912","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 46","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004912/suppl/GSM3004912_SH67M46_Cell1.txt.gz","2565","46","metastatic breast cancer","Yes","Serum"
"GSM3004913","Breast Cancer BC1870","GSM3004913","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004913/suppl/GSM3004913_SH67M46_Cell2.txt.gz","2565","59","metastatic breast cancer","No","Serum"
"GSM3004914","Breast Cancer BC1871","GSM3004914","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 42","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004914/suppl/GSM3004914_SH67M46_Cell3.txt.gz","2565","42","metastatic breast cancer","No","Serum"
"GSM3004915","Breast Cancer BC1872","GSM3004915","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 57","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004915/suppl/GSM3004915_SH67M46_Cell4.txt.gz","2565","57","metastatic breast cancer","No","Serum"
"GSM3004916","Breast Cancer BC1873","GSM3004916","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 43","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004916/suppl/GSM3004916_SH67M47_Cell1.txt.gz","2565","43","metastatic breast cancer","Yes","Serum"
"GSM3004917","Breast Cancer BC1874","GSM3004917","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 68","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004917/suppl/GSM3004917_SH67M47_Cell2.txt.gz","2565","68","metastatic breast cancer","No","Serum"
"GSM3004918","Breast Cancer BC1876","GSM3004918","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004918/suppl/GSM3004918_SH67M47_Cell4.txt.gz","2565","64","metastatic breast cancer","Yes","Serum"
"GSM3004919","Breast Cancer BC1877","GSM3004919","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004919/suppl/GSM3004919_SH67M49_Cell1.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3004920","Breast Cancer BC1878","GSM3004920","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 33","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004920/suppl/GSM3004920_SH67M49_Cell2.txt.gz","2565","33","metastatic breast cancer","No","Serum"
"GSM3004921","Breast Cancer BC1879","GSM3004921","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004921/suppl/GSM3004921_SH67T62_Cell3.txt.gz","2565","64","metastatic breast cancer","No","Serum"
"GSM3004922","Breast Cancer BC1880","GSM3004922","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004922/suppl/GSM3004922_SH67M49_Cell4.txt.gz","2565","60","metastatic breast cancer","No","Serum"
"GSM3004923","Breast Cancer BC1881","GSM3004923","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 57","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004923/suppl/GSM3004923_SH67M50_Cell1.txt.gz","2565","57","metastatic breast cancer","No","Serum"
"GSM3004924","Breast Cancer BC1882","GSM3004924","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004924/suppl/GSM3004924_SH67M50_Cell2.txt.gz","2565","44","metastatic breast cancer","No","Serum"
"GSM3004925","Breast Cancer BC1883","GSM3004925","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 55","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004925/suppl/GSM3004925_SH67M50_Cell3.txt.gz","2565","55","metastatic breast cancer","Yes","Serum"
"GSM3004926","Breast Cancer BC1884","GSM3004926","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004926/suppl/GSM3004926_SH67M50_Cell4.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3004927","Breast Cancer BC1885","GSM3004927","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 38","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004927/suppl/GSM3004927_SH67M51_Cell1.txt.gz","2565","38","metastatic breast cancer","Yes","Serum"
"GSM3004928","Breast Cancer BC1887","GSM3004928","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004928/suppl/GSM3004928_SH67M51_Cell3.txt.gz","2565","56","metastatic breast cancer","No","Serum"
"GSM3004929","Breast Cancer BC1888","GSM3004929","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 49","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004929/suppl/GSM3004929_SH67M51_Cell4.txt.gz","2565","49","metastatic breast cancer","No","Serum"
"GSM3004930","Breast Cancer BC1890","GSM3004930","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 46","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004930/suppl/GSM3004930_SH67M52_Cell2.txt.gz","2565","46","metastatic breast cancer","No","Serum"
"GSM3004931","Breast Cancer BC1891","GSM3004931","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 66","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004931/suppl/GSM3004931_SH67M52_Cell3.txt.gz","2565","66","metastatic breast cancer","No","Serum"
"GSM3004932","Breast Cancer BC1892","GSM3004932","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 35","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004932/suppl/GSM3004932_SH67M52_Cell4.txt.gz","2565","35","metastatic breast cancer","No","Serum"
"GSM3004933","Breast Cancer BC1893","GSM3004933","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 40","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004933/suppl/GSM3004933_SH67M53_Cell1.txt.gz","2565","40","metastatic breast cancer","Yes","Serum"
"GSM3004934","Breast Cancer BC1894","GSM3004934","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 52","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004934/suppl/GSM3004934_SH67M53_Cell2.txt.gz","2565","52","metastatic breast cancer","Yes","Serum"
"GSM3004935","Breast Cancer BC1895","GSM3004935","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004935/suppl/GSM3004935_SH67M53_Cell3.txt.gz","2565","65","metastatic breast cancer","Yes","Serum"
"GSM3004936","Breast Cancer BC1896","GSM3004936","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004936/suppl/GSM3004936_SH67M53_Cell4.txt.gz","2565","54","metastatic breast cancer","No","Serum"
"GSM3004937","Breast Cancer BC1897","GSM3004937","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 57","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004937/suppl/GSM3004937_SH67M54_Cell1.txt.gz","2565","57","metastatic breast cancer","Yes","Serum"
"GSM3004938","Breast Cancer BC1899","GSM3004938","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 62","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004938/suppl/GSM3004938_SH67M54_Cell3.txt.gz","2565","62","metastatic breast cancer","No","Serum"
"GSM3004939","Breast Cancer BC1900","GSM3004939","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 49","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004939/suppl/GSM3004939_SH67M54_Cell4.txt.gz","2565","49","metastatic breast cancer","Yes","Serum"
"GSM3004940","Breast Cancer BC1902","GSM3004940","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004940/suppl/GSM3004940_SH67M55_Cell2.txt.gz","2565","59","metastatic breast cancer","Yes","Serum"
"GSM3004941","Breast Cancer BC1903","GSM3004941","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 34","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004941/suppl/GSM3004941_SH67M55_Cell3.txt.gz","2565","34","metastatic breast cancer","No","Serum"
"GSM3004942","Breast Cancer BC1904","GSM3004942","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 68","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004942/suppl/GSM3004942_SH67M55_Cell4.txt.gz","2565","68","metastatic breast cancer","Yes","Serum"
"GSM3004943","Breast Cancer BC1905","GSM3004943","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004943/suppl/GSM3004943_SH67M56_Cell1.txt.gz","2565","60","metastatic breast cancer","No","Serum"
"GSM3004944","Breast Cancer BC1906","GSM3004944","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 46","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004944/suppl/GSM3004944_SH67M56_Cell2.txt.gz","2565","46","metastatic breast cancer","No","Serum"
"GSM3004945","Breast Cancer BC1907","GSM3004945","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 76","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004945/suppl/GSM3004945_SH67M56_Cell3.txt.gz","2565","76","metastatic breast cancer","No","Serum"
"GSM3004946","Breast Cancer BC1908","GSM3004946","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004946/suppl/GSM3004946_SH67M56_Cell4.txt.gz","2565","65","metastatic breast cancer","Yes","Serum"
"GSM3004947","Breast Cancer BC1909","GSM3004947","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004947/suppl/GSM3004947_SH67M57_Cell1.txt.gz","2565","60","metastatic breast cancer","Yes","Serum"
"GSM3004948","Breast Cancer BC1910","GSM3004948","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 52","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004948/suppl/GSM3004948_SH67T62_Cell4.txt.gz","2565","52","metastatic breast cancer","No","Serum"
"GSM3004949","Breast Cancer BC1911","GSM3004949","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 63","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004949/suppl/GSM3004949_SH67T63_Cell1.txt.gz","2565","63","metastatic breast cancer","No","Serum"
"GSM3004950","Breast Cancer BC1912","GSM3004950","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004950/suppl/GSM3004950_SH67T63_Cell2.txt.gz","2565","64","metastatic breast cancer","Yes","Serum"
"GSM3004951","Breast Cancer BC1913","GSM3004951","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 58","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004951/suppl/GSM3004951_SH67T63_Cell3.txt.gz","2565","58","metastatic breast cancer","Yes","Serum"
"GSM3004952","Breast Cancer BC1914","GSM3004952","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 75","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004952/suppl/GSM3004952_SH67M58_Cell2.txt.gz","2565","75","metastatic breast cancer","No","Serum"
"GSM3004953","Breast Cancer BC1915","GSM3004953","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004953/suppl/GSM3004953_SH67T63_Cell4.txt.gz","2565","56","metastatic breast cancer","No","Serum"
"GSM3004954","Breast Cancer BC1916","GSM3004954","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004954/suppl/GSM3004954_SH67W01_Cell1.txt.gz","2565","56","metastatic breast cancer","Yes","Serum"
"GSM3004955","Breast Cancer BC1917","GSM3004955","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 73","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004955/suppl/GSM3004955_SH67M59_Cell1.txt.gz","2565","73","metastatic breast cancer","No","Serum"
"GSM3004956","Breast Cancer BC1918","GSM3004956","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004956/suppl/GSM3004956_SH67M59_Cell2.txt.gz","2565","60","metastatic breast cancer","No","Serum"
"GSM3004957","Breast Cancer BC1919","GSM3004957","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004957/suppl/GSM3004957_SH67M59_Cell3.txt.gz","2565","44","metastatic breast cancer","Yes","Serum"
"GSM3004958","Breast Cancer BC1920","GSM3004958","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 52","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004958/suppl/GSM3004958_SH67M59_Cell4.txt.gz","2565","52","metastatic breast cancer","No","Serum"
"GSM3004959","Breast Cancer BC1921","GSM3004959","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 50","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004959/suppl/GSM3004959_SH67M60_Cell1.txt.gz","2565","50","metastatic breast cancer","Yes","Serum"
"GSM3004960","Breast Cancer BC1922","GSM3004960","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 69","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004960/suppl/GSM3004960_SH67M60_Cell2.txt.gz","2565","69","metastatic breast cancer","Yes","Serum"
"GSM3004961","Breast Cancer BC1923","GSM3004961","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 74","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004961/suppl/GSM3004961_SH67M60_Cell3.txt.gz","2565","74","metastatic breast cancer","No","Serum"
"GSM3004962","Breast Cancer BC1924","GSM3004962","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 42","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004962/suppl/GSM3004962_SH67M60_Cell4.txt.gz","2565","42","metastatic breast cancer","No","Serum"
"GSM3004963","Breast Cancer BC1925","GSM3004963","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004963/suppl/GSM3004963_SH67M61_Cell1.txt.gz","2565","54","metastatic breast cancer","Yes","Serum"
"GSM3004964","Breast Cancer BC1926","GSM3004964","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 55","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004964/suppl/GSM3004964_SH67W01_Cell2.txt.gz","2565","55","metastatic breast cancer","No","Serum"
"GSM3004965","Breast Cancer BC1928","GSM3004965","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004965/suppl/GSM3004965_SH67M61_Cell4.txt.gz","2565","54","metastatic breast cancer","Yes","Serum"
"GSM3004966","Breast Cancer BC1929","GSM3004966","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 53","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004966/suppl/GSM3004966_SH67M62_Cell1.txt.gz","2565","53","metastatic breast cancer","Yes","Serum"
"GSM3004967","Breast Cancer BC1930","GSM3004967","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004967/suppl/GSM3004967_SH67M62_Cell2.txt.gz","2565","64","metastatic breast cancer","No","Serum"
"GSM3004968","Breast Cancer BC1931","GSM3004968","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 73","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004968/suppl/GSM3004968_SH67M62_Cell3.txt.gz","2565","73","metastatic breast cancer","Yes","Serum"
"GSM3004969","Breast Cancer BC1932","GSM3004969","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 47","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004969/suppl/GSM3004969_SH67M62_Cell4.txt.gz","2565","47","metastatic breast cancer","No","Serum"
"GSM3004970","Breast Cancer BC1933","GSM3004970","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 68","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004970/suppl/GSM3004970_SH67R01_Cell1.txt.gz","2565","68","metastatic breast cancer","No","Serum"
"GSM3004971","Breast Cancer BC1934","GSM3004971","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 42","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004971/suppl/GSM3004971_SH67R01_Cell2.txt.gz","2565","42","metastatic breast cancer","No","Serum"
"GSM3004972","Breast Cancer BC1935","GSM3004972","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004972/suppl/GSM3004972_SH67R01_Cell3.txt.gz","2565","64","metastatic breast cancer","No","Serum"
"GSM3004973","Breast Cancer BC1936","GSM3004973","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 66","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004973/suppl/GSM3004973_SH67W01_Cell3.txt.gz","2565","66","metastatic breast cancer","No","Serum"
"GSM3004974","Breast Cancer BC1937","GSM3004974","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 69","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004974/suppl/GSM3004974_SH67R02_Cell1.txt.gz","2565","69","metastatic breast cancer","No","Serum"
"GSM3004975","Breast Cancer BC1938","GSM3004975","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 55","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004975/suppl/GSM3004975_SH67R02_Cell2.txt.gz","2565","55","metastatic breast cancer","No","Serum"
"GSM3004976","Breast Cancer BC1939","GSM3004976","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004976/suppl/GSM3004976_SH67R02_Cell3.txt.gz","2565","65","metastatic breast cancer","No","Serum"
"GSM3004977","Breast Cancer BC1940","GSM3004977","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 76","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004977/suppl/GSM3004977_SH67R02_Cell4.txt.gz","2565","76","metastatic breast cancer","Yes","Serum"
"GSM3004978","Breast Cancer BC1941","GSM3004978","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 67","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004978/suppl/GSM3004978_SH67R03_Cell1.txt.gz","2565","67","metastatic breast cancer","No","Serum"
"GSM3004979","Breast Cancer BC1942","GSM3004979","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 65","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004979/suppl/GSM3004979_SH67R03_Cell2.txt.gz","2565","65","metastatic breast cancer","No","Serum"
"GSM3004980","Breast Cancer BC1943","GSM3004980","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 58","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004980/suppl/GSM3004980_SH67R03_Cell3.txt.gz","2565","58","metastatic breast cancer","No","Serum"
"GSM3004981","Breast Cancer BC1944","GSM3004981","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 41","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004981/suppl/GSM3004981_SH67W01_Cell4.txt.gz","2565","41","metastatic breast cancer","No","Serum"
"GSM3004982","Breast Cancer BC1945","GSM3004982","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 48","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004982/suppl/GSM3004982_SH67R04_Cell1.txt.gz","2565","48","metastatic breast cancer","No","Serum"
"GSM3004983","Breast Cancer BC1946","GSM3004983","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004983/suppl/GSM3004983_SH67R04_Cell2.txt.gz","2565","56","metastatic breast cancer","No","Serum"
"GSM3004984","Breast Cancer BC1947","GSM3004984","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004984/suppl/GSM3004984_SH67W04_Cell1.txt.gz","2565","59","metastatic breast cancer","No","Serum"
"GSM3004985","Breast Cancer BC1948","GSM3004985","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 53","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004985/suppl/GSM3004985_SH67W04_Cell2.txt.gz","2565","53","metastatic breast cancer","No","Serum"
"GSM3004986","Breast Cancer BC1949","GSM3004986","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 78","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004986/suppl/GSM3004986_SH67W04_Cell3.txt.gz","2565","78","metastatic breast cancer","No","Serum"
"GSM3004987","Breast Cancer BC1950","GSM3004987","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 57","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004987/suppl/GSM3004987_SH67W04_Cell4.txt.gz","2565","57","metastatic breast cancer","No","Serum"
"GSM3004988","Breast Cancer BC1951","GSM3004988","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 46","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004988/suppl/GSM3004988_SH67R05_Cell3.txt.gz","2565","46","metastatic breast cancer","No","Serum"
"GSM3004989","Breast Cancer BC1952","GSM3004989","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 49","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004989/suppl/GSM3004989_SH67W06_Cell1.txt.gz","2565","49","metastatic breast cancer","No","Serum"
"GSM3004990","Breast Cancer BC1953","GSM3004990","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 45","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004990/suppl/GSM3004990_SH67W06_Cell2.txt.gz","2565","45","metastatic breast cancer","No","Serum"
"GSM3004991","Breast Cancer BC1954","GSM3004991","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004991/suppl/GSM3004991_SH67W06_Cell3.txt.gz","2565","56","metastatic breast cancer","Yes","Serum"
"GSM3004992","Breast Cancer BC1955","GSM3004992","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004992/suppl/GSM3004992_SH67W06_Cell4.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3004993","Breast Cancer BC1956","GSM3004993","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 66","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004993/suppl/GSM3004993_SH67W07_Cell1.txt.gz","2565","66","metastatic breast cancer","No","Serum"
"GSM3004994","Breast Cancer BC1957","GSM3004994","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 51","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004994/suppl/GSM3004994_SH67W07_Cell2.txt.gz","2565","51","metastatic breast cancer","No","Serum"
"GSM3004995","Breast Cancer BC1958","GSM3004995","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 64","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004995/suppl/GSM3004995_SH67W07_Cell3.txt.gz","2565","64","metastatic breast cancer","Yes","Serum"
"GSM3004996","Breast Cancer BC1959","GSM3004996","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 69","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004996/suppl/GSM3004996_SH67W07_Cell4.txt.gz","2565","69","metastatic breast cancer","No","Serum"
"GSM3004997","Breast Cancer BC1960","GSM3004997","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 59","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004997/suppl/GSM3004997_SH67W09_Cell1.txt.gz","2565","59","metastatic breast cancer","Yes","Serum"
"GSM3004998","Breast Cancer BC1961","GSM3004998","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 43","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004998/suppl/GSM3004998_SH67W09_Cell2.txt.gz","2565","43","metastatic breast cancer","No","Serum"
"GSM3004999","Breast Cancer BC1962","GSM3004999","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 41","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3004nnn/GSM3004999/suppl/GSM3004999_SH67W09_Cell3.txt.gz","2565","41","metastatic breast cancer","Yes","Serum"
"GSM3005000","Breast Cancer BC1963","GSM3005000","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 45","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005000/suppl/GSM3005000_SH67R09_Cell3.txt.gz","2565","45","metastatic breast cancer","Yes","Serum"
"GSM3005001","Breast Cancer BC1964","GSM3005001","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005001/suppl/GSM3005001_SH67W09_Cell4.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3005002","Breast Cancer BC1965","GSM3005002","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 71","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005002/suppl/GSM3005002_SH67W11_Cell1.txt.gz","2565","71","metastatic breast cancer","No","Serum"
"GSM3005003","Breast Cancer BC1966","GSM3005003","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 75","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005003/suppl/GSM3005003_SH67W11_Cell2.txt.gz","2565","75","metastatic breast cancer","No","Serum"
"GSM3005004","Breast Cancer BC1968","GSM3005004","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 56","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005004/suppl/GSM3005004_SH67W11_Cell4.txt.gz","2565","56","metastatic breast cancer","No","Serum"
"GSM3005005","Breast Cancer BC1970","GSM3005005","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 60","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005005/suppl/GSM3005005_SH67W16_Cell1.txt.gz","2565","60","metastatic breast cancer","Yes","Serum"
"GSM3005006","Breast Cancer BC1971","GSM3005006","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005006/suppl/GSM3005006_SH67W16_Cell2.txt.gz","2565","44","metastatic breast cancer","No","Serum"
"GSM3005007","Breast Cancer BC1972","GSM3005007","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 61","new distant metastasis: No","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005007/suppl/GSM3005007_SH67W16_Cell3.txt.gz","2565","61","metastatic breast cancer","No","Serum"
"GSM3005008","Breast Cancer BC1975","GSM3005008","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 40","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005008/suppl/GSM3005008_SH67W17_Cell2.txt.gz","2565","40","metastatic breast cancer","Yes","Serum"
"GSM3005009","Breast Cancer BC1976","GSM3005009","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 48","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005009/suppl/GSM3005009_SH67W17_Cell3.txt.gz","2565","48","metastatic breast cancer","Yes","Serum"
"GSM3005010","Breast Cancer BC1977","GSM3005010","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 44","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005010/suppl/GSM3005010_SH67R13_Cell1.txt.gz","2565","44","metastatic breast cancer","Yes","Serum"
"GSM3005011","Breast Cancer BC1978","GSM3005011","Public on Feb 16 2019","Feb 15 2018","Feb 16 2019","RNA","1","Serum from breast cancer patient during eribulin treatment","Homo sapiens","disease state: metastatic breast cancer","age: 54","new distant metastasis: Yes","tissue: Serum","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3005nnn/GSM3005011/suppl/GSM3005011_SH67W17_Cell4.txt.gz","2565","54","metastatic breast cancer","Yes","Serum"
